share_log

Pfizer | DEFA14A: Others

Pfizer | DEFA14A: Others

輝瑞 | DEFA14A:其他
SEC announcement ·  04/11 23:00
牛牛AI助理已提取核心訊息
Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Pfizer as the registrant, indicating that no third parties were involved in the filing. The company confirmed that no filing fee was required for this submission. The purpose of the filing and the contents of the additional materials have not been specified in the announcement.
Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Pfizer as the registrant, indicating that no third parties were involved in the filing. The company confirmed that no filing fee was required for this submission. The purpose of the filing and the contents of the additional materials have not been specified in the announcement.
根據1934年《證券交易法》第14(a)條,輝瑞公司已向美國證券交易委員會(SEC)提交了明確的補充材料,作爲其委託聲明附表14A的一部分。這些材料由輝瑞作爲註冊人提交,表明申請中沒有第三方參與。該公司證實,此次提交不需要任何申請費。公告中沒有具體說明申報目的和補充材料的內容。
根據1934年《證券交易法》第14(a)條,輝瑞公司已向美國證券交易委員會(SEC)提交了明確的補充材料,作爲其委託聲明附表14A的一部分。這些材料由輝瑞作爲註冊人提交,表明申請中沒有第三方參與。該公司證實,此次提交不需要任何申請費。公告中沒有具體說明申報目的和補充材料的內容。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。